Tamsulosin for Thyroid Lid Retraction

Status Recruiting

Clinical Trial Summary

The purpose of this study is to examine the effect of using Tamsulosin for treatment of eyelid retraction as part of thyroid eye disease. The treatment will be offered to all thyroid patients suffering from eyelid retraction who are treated at the thyroid clinic in Sheba's Ophthalmology department. All patient will receive information about the drug Tamsulosin, the possible side effects, and the alternative treatment options for retraction. Patients recruited will take 0.4mg/day Tamsulosin for 3 months and will have follow-ups at 1 week, 1 month and 3 months to evaluate the retraction status.

Clinical Trial Description

Thyroid eye disease is a common autoimmune disorder caused by antibodies directed against receptors present in the thyroid cells and extra-ocular muscles and soft tissue of the orbit. The disorder is characterised by enlargement of the extra-ocular muscles, fatty and connective tissue volume. Upper lid retraction is the most common sign of the eye disease (present in up to 92%). The causes for retraction are not fully understood. It may be related to inflammation of the Levator muscle and the Muller muscle, or related to over sympathetic activity causing overstimulation of the Muller muscle. Upper lid retraction severity can range from very light to severe, with scleral show, eye dryness and even exposure keratopathy. Additionally it can have a very significant effect on the patient's appearance (a constant surprised look). Treatments for lid retraction include aggressive lubrication and tarsorrhaphy if needed (sewing the eyelids together). The Muller is a smooth muscle which elevates the upper eyelid and is sympathetically innervated (alpha receptor). The drug Tamsulosin which is a selective alpha1 receptor antagonist is commonly used today for benign prostatic hyperplasia (relaxing the prostate muscle). In this study we would like to test using Tamsulosin for treatment of lid retraction caused by thyroid eye disease. We hypothesise that the relaxation of the Muller muscle may have a beneficial effect on the retraction. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04359979
Study type	Interventional
Source	Sheba Medical Center
Contact	Oded Sagiv, MD
Phone	97235302874
Email	Oded.Sagiv@sheba.health.gov.il
Status	Recruiting
Phase	N/A
Start date	May 1, 2020
Completion date	December 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04583735` - A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease	Phase 4
Active, not recruiting	`NCT05002998` - TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study	Phase 4
Withdrawn	`NCT02422368` - The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease	Phase 2/Phase 3
Completed	`NCT03298867` - Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study	Phase 3
Recruiting	`NCT05987423` - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease	Phase 3
Recruiting	`NCT06112340` - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3
Recruiting	`NCT05517447` - Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease	Phase 3
Terminated	`NCT04737330` - A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)	Phase 3
Recruiting	`NCT05517421` - Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease	Phase 3
Recruiting	`NCT04311606` - Anti-VEGF Therapy for Acute Thyroid Eye Disease	Phase 2
Recruiting	`NCT06106828` - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease (SatraGO-2)	Phase 3
Recruiting	`NCT06021054` - A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)	Phase 3
Not yet recruiting	`NCT06413043` - Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy	N/A
Not yet recruiting	`NCT06401044` - A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease	Phase 1
Recruiting	`NCT06384547` - A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)	Phase 3
Recruiting	`NCT06367517` - Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Recruiting	`NCT06275373` - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Enrolling by invitation	`NCT05241626` - AS-OCT of the Cornea in Thyroid Diseases
Active, not recruiting	`NCT05776121` - Study of ZB001 in Chinese Patients With Thyroid Eye Disease	Phase 1
Recruiting	`NCT06226545` - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease	Phase 2